The global pharmaceutical industry gathers this week at CPHI Frankfurt 2025 from October 28–30. As a global leading ...

MALVERN, Pa.--(BUSINESS WIRE)--Alliance Pharma, a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, and Drug Development ...

ChemDiv, a global provider of integrated drug discovery solutions, today announced the extension of its Chemistry, Manufacturing and Controls (CMC) services collaboration supporting the clinical ...

Enhanc3D Genomics has announced the launch of a suite of integrated multi-omics solutions to accelerate and improve the precision of drug discovery. The new 3D multi-omics offerings were designed to ...

HUNT VALLEY, Md.--(BUSINESS WIRE)--Pharmaceutics International, Inc. (Pii), a trusted provider of pharmaceutical development and manufacturing services, today announced the launch of its pioneering ...

RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President ...

Thermo Fisher Scientific says addressing the need for prefilled syringes is among potential production bottlenecks, the company is working to address. Thermo Fisher’s Accelerator™ Drug Development ...

VANCOUVER, BC / ACCESS Newswire / July 8, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a development-stage biopharmaceutical company specializing in ...

MANCHESTER, United Kingdom and HYDERABAD, India, Oct. 08, 2025 (GLOBE NEWSWIRE) — Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), Agility Life Sciences, and Centrix Pharma Solutions today announced ...

RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President of Drug ...

MSIDA, Malta, Oct. 05, 2017 (GLOBE NEWSWIRE) -- DRGT, a specialty pharmaceutical company, today announced the results of its Phase I study of DRGT18-2, a novel formulation of Sirolimus (Rapamune®), ...